NCT03820388 is a Phase 4 clinical trial of Propofol 2mg/kg in Surgery, sponsored by University of California, Davis.

Who is sponsoring NCT03820388?

NCT03820388 is sponsored by University of California, Davis.

What drugs are being tested in NCT03820388?

Interventions in NCT03820388: Propofol 2mg/kg, Etomidate 0.3 mg/kg, Propofol 1 mg/kg, Etomidate 0.15 mg/kg.

Is NCT03820388 still recruiting?

NCT03820388 is currently completed. Last updated 23 February 2021.

Are results published for NCT03820388?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-02-23 · How we verify

NCT03820388

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Etomidate Plus Propofol, Etomidate Alone on Induction of Anesthesia

Completed Phase 4 Results posted Last updated 23 February 2021

What this trial tests

Phase 4 trial testing Propofol 2mg/kg in Surgery in 75 participants. Completed in 13 July 2018.

Timeline

1 December 2017

Primary endpoint
13 July 2018

13 July 2018

Quick facts

Lead sponsor	University of California, Davis
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	75
Start date	1 December 2017
Primary completion	13 July 2018
Estimated completion	13 July 2018
Sites	1 location across United States

Drugs / interventions tested

Propofol 2mg/kg — full drug profile →
Etomidate 0.3 mg/kg — full drug profile →
Propofol 1 mg/kg — full drug profile →
Etomidate 0.15 mg/kg — full drug profile →

Conditions studied

Surgery — all drugs for Surgery →

Sponsor

University of California, Davis

Who can join

18 and older, any sex, with Surgery. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Blood Pressure Primary · 10 minutes after induction (intraoperative)

Blood Pressure Fluctuations during Induction; change of blood pressure from baseline from induction to 10 min after induction.

Group	Value	95% CI
Propofol Group	105	± 16
Etomidate Group	122	± 23
Propofol Plus Etomidate Group	117.88	± 18

Heart Rate Primary · 10 minutes after induction (intraoperative)

Heart Rate changes during induction (Beats Per min)

Group	Value	95% CI
Propofol Group	77	± 17
Etomidate Group	74	± 12
Propofol Plus Etomidate Group	74	± 11

Pain at Injection Site Secondary · intraoperative

Pain on injection will be measured using 4 graded scale; 0 = no pain, 1 = verbal complaint of pain, 2 = withdrawal of arm, 3 = both verbal complaint and withdrawal of arm.

Group	Value	95% CI
Propofol Group	7
Etomidate Group	0
Propofol Plus Etomidate Group	0

Myoclonic Movements Secondary · intraoperative

The incidence and degree of myoclonic movements also recorded as follows: 0 = no myoclonic movements, 1 = minor myoclonic movements, 2 = moderate myoclonic movements, 3 = major myoclonic movements.

Group	Value	95% CI
Propofol Group	1
Etomidate Group	6
Propofol Plus Etomidate Group	1

Post-operative Nausea and Vomiting Secondary · 24 hours post-operation

Presence of post-operative nausea or vomiting (yes/no).

Group	Value	95% CI
Propofol Group	0
Etomidate Group	1
Propofol Plus Etomidate Group	2

Sedation Depth Secondary · 30 minutes post-induction

Sedation depth using bispectral index (BIS). BIS scores range from 0-100. A value of 0 indicates no EEG activity, 40-60 indicates an appropriate level of general anesthesia, and 90-100 is typical of a state of wakefulness.

Group	Value	95% CI
Propofol Group	30	± 8.4
Etomidate Group	38	± 11
Propofol Plus Etomidate Group	38	± 13

Eyelash Reflex Disappear Time Secondary · Post induction, up to 1 hour

Time to disappearance of eyelash reflex after induction.

Group	Value	95% CI
Propofol Group	31.9	± 8.3
Etomidate Group	34.5	± 7.5
Propofol Plus Etomidate Group	32.4	± 9

Intubation Time Secondary · Up to 2 hours

Duration of orotracheal intubation.

Group	Value	95% CI
Propofol Group	92	± 9.6
Etomidate Group	95	± 8.9
Propofol Plus Etomidate Group	93	± 9.5

Sponsor's own description

Comparison of Etomidate plus Propofol vs. Propofol or Etomidate alone during induction of anesthesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Surgery

Currently open trials in the same condition.

NCT07369921 — Pediatric Pilonidal Sinus Surgical Treatment · NA · recruiting
NCT07362303 — Neuralert Stroke Monitor Trial · NA · recruiting
NCT07404163 — Walkway Used in Postoperative Mobilization · NA · active not recruiting
NCT07218289 — Green Light for Post-Operative Wellness · NA · recruiting
NCT07342751 — The Effect of Listening to Music During Mobilization on Pain and Fear in Children Undergoing Abdominal Surgery · NA · active not recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03820388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03820388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing